BeiGene Switches To Combo Therapy Approach For Brukinsa
Executive Summary
BeiGene exec reveals Chinese firm's changing development strategy around key asset as further clinical results emerge.
You may also be interested in...
Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go
Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.
Recbio First Biotech To Brave A Hong Kong IPO In 2022
Chinese vaccine maker Recbio hopes an IPO in Hong Kong will bring investor attention to its mRNA COVID vaccine with potential against the Omicron variant.
China Aims To Synchronize With Global Drug Approvals By 2025
China’s new Five-Year Plan for drug quality aims to address hurdles in clinical study ethics committee review while leaving out other restrictions including genetic material export and substandard clinical sites.